Enzyme, competitive inhibitor

In the case of competitive inhibition, the equilibrium between the enzyme, E, the inhibitor, 1, and the enzyme-inhibitor complex, El, is described by the equilibrium constant Ki. 

The enzyme catalyzes the hydrolysis of an amide bond linkage with water via a covalent enzyme-inhibitor adduct. Benzoxazinones such as 2-ethoxy-4H-3,l-benzoxazin-4-one [41470-88-6] (23) have been shown to completely inactivate the enzyme in a competitive and stoichiometric fashion (Eigure 5). The intermediate (25) is relatively stable compared to the enzyme-substrate adduct due to the electron-donating properties of the ortho substituents. The complex (25) has a half-life of reactivation of 11 hours. 

The three most common types of inhibitors in enzymatic reactions are competitive, non-competitive, and uncompetitive. Competitive inliibition occurs when tlie substrate and inhibitor have similar molecules that compete for the identical site on the enzyme. Non-competitive inhibition results in enzymes containing at least two different types of sites. The inhibitor attaches to only one type of site and the substrate only to the other. Uncompetitive inhibition occurs when the inhibitor deactivates the enzyme substrate complex. The effect of an inhibitor is determined by measuring the enzyme velocity at various... 

Generally inhibitors are competitive or non-competitive with substrates. In competitive inhibition, the interaction of the enzyme with the substrate and competitive inhibitor instead of the substrate can be analysed with the sequence of reactions taking place as a result, a complex of the enzyme-inhibitor (El) is formed. The reaction sets at equilibrium and the final step shows the product is formed. The enzyme must get free, but the enzyme attached to the inhibitor does not have any chance to dissociate from the El complex. The El formed is not available for conversion of substrate free enzymes are responsible for that conversion. The presence of inhibitor can cause the reaction rate to be slower than the ordinary reaction, in the absence of the inhibitor. The sequence of reaction mechanisms is ... 

In such inhibition, the inhibitor and die substrate can simultaneously bind to the enzyme. The nature of the enzyme-inhibitor-substrate binding has resulted in a ternary complex defined as EIS. The Ks and Kt are identical to the corresponding dissociation constants. It is also assumed that the EIS does not react further and is unable to deliver any product P. The rate equation for non-competitive inhibition, unvAX, is influenced ... 

Substrate and product inhibitions analyses involved considerations of competitive, uncompetitive, non-competitive and mixed inhibition models. The kinetic studies of the enantiomeric hydrolysis reaction in the membrane reactor included inhibition effects by substrate (ibuprofen ester) and product (2-ethoxyethanol) while varying substrate concentration (5-50 mmol-I ). The initial reaction rate obtained from experimental data was used in the primary (Hanes-Woolf plot) and secondary plots (1/Vmax versus inhibitor concentration), which gave estimates of substrate inhibition (K[s) and product inhibition constants (A jp). The inhibitor constant (K[s or K[v) is a measure of enzyme-inhibitor affinity. It is the dissociation constant of the enzyme-inhibitor complex. 

In non-competitive inhibition, the substrate (S) and inhibitor (I) have equal potential to bind to the free enzyme (E). The inhibitor forms a ternary complex with enzyme-substrate (ES) whereas the substrate will form another ternary complex with enzyme-inhibitor (El). Since the non-competitive inhibitor had no effect on the binding of substrate to the enzyme, the Km value remained consistent (or unchanged). There are two different ways for the formation of ESI ternary complex this complex would not form the product and therefore was decreased. Non-competitive inhibitor had no effect on substrate binding or the enzyme-substrate affinity, therefore the apparent rate constant (K ) was unchanged.5 A possible reason for product inhibition was because of the nature of 2-ethoxyethanol,... 

The inactivation is normally a first-order process, provided that the inhibitor is in large excess over the enzyme and is not depleted by spontaneous or enzyme-catalyzed side-reactions. The observed rate-constant for loss of activity in the presence of inhibitor at concentration [I] follows Michaelis-Menten kinetics and is given by kj(obs) = ki(max) [I]/(Ki + [1]), where Kj is the dissociation constant of an initially formed, non-covalent, enzyme-inhibitor complex which is converted into the covalent reaction product with the rate constant kj(max). For rapidly reacting inhibitors, it may not be possible to work at inhibitor concentrations near Kj. In this case, only the second-order rate-constant kj(max)/Kj can be obtained from the experiment. Evidence for a reaction of the inhibitor at the active site can be obtained from protection experiments with substrate [S] or a reversible, competitive inhibitor [I(rev)]. In the presence of these compounds, the inactivation rate Kj(obs) should be diminished by an increase of Kj by the factor (1 + [S]/K, ) or (1 + [I(rev)]/I (rev)). From the dependence of kj(obs) on the inhibitor concentration [I] in the presence of a protecting agent, it may sometimes be possible to determine Kj for inhibitors that react too rapidly in the accessible range of concentration. ... 

Figure 3.2 Cartoon representations of the three major forms of reversible inhibitor interactions with enzymes (A) competitive inhibition (B) noncompetitive inhibition (C) uncompetitive inhibition. Source-. From Copeland (2000).

Table 3.2 Some examples of competitive enzyme inhibitors in clinical use...

Figure 3.16 Effects of substrate buildup in a metabolic pathway on the inhibition of an enzyme by competitive (closed circles) and uncompetitive (open circles) inhibitors of equal affinity for the target enzyme.

In this chapter we described the thermodynamics of enzyme-inhibitor interactions and defined three potential modes of reversible binding of inhibitors to enzyme molecules. Competitive inhibitors bind to the free enzyme form in direct competition with substrate molecules. Noncompetitive inhibitors bind to both the free enzyme and to the ES complex or subsequent enzyme forms that are populated during catalysis. Uncompetitive inhibitors bind exclusively to the ES complex or to subsequent enzyme forms. We saw that one can distinguish among these inhibition modes by their effects on the apparent values of the steady state kinetic parameters Umax, Km, and VmdX/KM. We further saw that for bisubstrate reactions, the inhibition modality depends on the reaction mechanism used by the enzyme. Finally, we described how one may use the dissociation constant for inhibition (Kh o.K or both) to best evaluate the relative affinity of different inhibitors for ones target enzyme, and thus drive compound optimization through medicinal chemistry efforts. 

Figure 5.4 Effects of [S] KAl ratio on the apparent IC value for competitive (closed circles), noncompetitive (closed squares a = 1) and uncompetitive (open circles) enzyme inhibitors. Note that the x-axis is plotted on a logarithmic scale for clarity.

Figure 7.6 Double reciprocal plot for a tight binding competitive enzyme inhibitor, demonstrating the curvature of such plots. The dashed lines represent an attempt to fit the data at lower substrate concentrations to linear equations. This highlights how double reciprocal plots for tight binding inhibitors can be misleading, especially when data are collected only over a limited range of substrate concentrations.

Figure 7.7 Plot of IC50 as a function of substrate concentration (plotted as the ratio [S]/ATM on the x-axis) for tight binding competitive (closed circles) and tight binding uncompetitive (open circles) enzyme inhibitors.

A competitive version of ABPP identifies the target(s) and assesses the selectivity of an enzyme inhibitor in biological systems by gauging how well the inhibitor slows the enzyme s reaction with an ABP. For example, fluorophosphonate ABP 3 was used to profile the selectivity of fatty acid amide hydrolase (FAAH) inhibitors within the serine hydrolase superfamily [27] (FAAH hydrolyzes endocannabinoids such as anandamide). Serine hydrolases that exhibited reduced labeling by the probe in the presence of inhibitor were scored as targets of the inhibitor. Urea FAAH inhibitors exemplified by PF-3845 (5) that covalently modify the active-site serine nucleophile of FAAH were found to be exquisitely selective for FAAH in brain and liver... 

These examples highlight the utility of competitive ABPP and CC-ABPP to identify the targets and selectivity of existing small molecules, to identify novel covalent enzyme inhibitors, and to characterize enzymes of unknown function. 

Enzymes can be used not only for the determination of substrates but also for the analysis of enzyme inhibitors. In this type of sensors the response of the detectable species will decrease in the presence of the analyte. The inhibitor may affect the vmax or KM values. Competitive inhibitors, which bind to the same active site than the substrate, will increase the KM value, reflected by a change on the slope of the Lineweaver-Burke plot but will not change vmax. Non-competitive inhibitors, i.e. those that bind to another site of the protein, do not affect KM but produce a decrease in vmax. For instance, the acetylcholinesterase enzyme is inhibited by carbamate and organophosphate pesticides and has been widely used for the development of optical fiber sensors for these compounds based on different chemical transduction schemes (hydrolysis of a colored substrate, pH changes). 

Plotting 1/V versus 1/[S], one obtains a straight line having a slope of Km/Vmax with a y-axis intercept of l/VmAX and an x-intercept of - 1/Km as shown in Figure 2.13. Lineweaver-Burk plots of enzyme activity in the presence of an inhibitor can distinguish the type of inhibitor. Competitive inhibitors have a molecular structure similar to that of the substrate and will alter Km but not VnrAX because they compete with the substrate for binding at the enzyme s active site but do not change the enzyme s affinity for substrate. Noncompetitive inhibitors bear no structural similarity to the substrate but bind the free enzyme or enzyme-substrate... 

As discussed above, the degree of inhibition is indicated by the ratio of k3/k and defines an inhibitor constant (Kj) [Eq. (3.19)], whose value reports the dissociation of the enzyme-inhibitor complex (El) [Eq. (3.20)]. Deriving the equation for competitive inhibition under steady-state conditions leads to Eq. (3.21). Reciprocal plots of 1/v versus 1/5 (Lineweaver-Burk plots) as a function of various inhibitor concentrations readily reveal competitive inhibition and define their characteristic properties (Fig. 3.5). Notice that Vmax does not change. Irrespective of how much competitive inhibitor is present, its effect can be overcome by adding a sufficient amount of substrate, i.e., substrate can be added until Vmax is reached. Also notice that K i does change with inhibitor concentration therefore the Km that is measured in the presence of inhibitor is an apparent Km- The true KM can only be obtained in the absence of inhibitor. 

Enzymatic reactions can be impeded by the addition of exogenous molecules. This is how drugs are used to control biochemical reactions, and most drugs are used for inhibitory functions. Drugs may function as competitive inhibitors or as noncompetitive inhibitors. Competitive inhibitors compete with the substrates for binding to the active sites, whereas noncompetitive inhibitors bind to another location (allosteric site) but affect the active site and its consequential interactions with the substrates. Some drugs used as enzyme inhibitors are the following ... 

For example, experimental data might reveal that a novel enzyme inhibitor causes a concentration-dependent increase in Km, with no effect on and with Lineweaver-Burk plots indicative of competitive inhibition. Flowever, even at very high inhibitor concentrations and very low substrate concentrations, it is observed that the degree of inhibition levels off when some 60% of activity still remains. Furthermore, it has been confirmed that only one enzyme is present, and all appropriate blank rates have been accounted for. It is clear that full competitive inhibition cannot account for such observations because complete inhibition can be attained at infinitely high concentrations of a full competitive inhibitor. Thus, it is likely that the inhibitor binds to the enzyme at an allosteric site. 

In equations 3 and 4, the temperatures are expressed in degrees Kelvin I is the concentration of the competitive inhibitor, and K, the dissociation constant for the enzyme-inhibitor (El) complex at the temperature Tg. 

Competitive inhibitors bind to specific groups in the enzyme active site to form an enzyme-inhibitor complex. The inhibitor and substrate compete for the same site, so that the substrate is prevented from binding. This is usually because the substrate and inhibitor share considerable stmctural similarity. Catalysis is diminished because a lower proportion of molecules have a bound substrate. Inhibition can be relieved by increasing the concentration of substrate. Some simple examples are shown below. Thus, sulfanilamide is an inhibitor of the enzyme that incorporates j9-aminobenzoic acid into folic acid, and has antibacterial properties by restricting folic acid biosynthesis in the bacterium (see Box 11.13). Some phenylethylamine derivatives, e.g. phenelzine, provide useful antidepressant drags by inhibiting the enzyme monoamine oxidase. The cA-isomer maleic acid is a powerful inhibitor of the enzyme that utilizes the trans-isomer fumaric acid in the Krebs cycle. 

Most enzyme inhibitors act reversibly—i. e., they do not cause any permanent changes in the enzyme. However, there are also irreversible inhibitors that permanently modify the target enzyme. The mechanism of action of an inhibitor—its inhibition type—can be determined by comparing the kinetics (see p.92) of the inhibited and uninhibited reactions (B). This makes it possible to distinguish competitive inhibitors (left) from noncompetitive inhibitors (right), for example. Allosteric inhibition is particularly important for metabolic regulation (see below). 

Antimetabolites are enzyme inhibitors (see p. 96) that selectively block metabolic pathways. The majority of clinically important cytostatic drugs act on nucleotide biosynthesis. Many of these are modified nucleobases or nucleotides that competitively inhibit their target enzymes (see p. 96). Many are also incorporated into the DNA, thereby preventing replication. 

---